Andrew John Armstrong | Scholars@Duke

Andrew John Armstrong
Professor of Medicine

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

Office Hours

Tuesdays, Wednesdays and Fridays. Contact Peggy Cook, my assistant at peggy.cook@dm.duke.edu for appointments. Or 919-668-4667.

Current Appointments & Affiliations

Professor of Medicine, Medicine, Medical Oncology, Medicine 2018
Associate Professor in Pharmacology and Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2015
Professor in Surgery, Surgery, Urology, Surgery 2018
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2006

Contact Information

Duke Box 103861, Durham, NC 27710
GSRB1 Room 3006, 905 La Salle St, Durham, NC 27710
andrew.armstrong@duke.edu (919) 668-8797

Background
Education, Training, & Certifications
- M.Sc., Johns Hopkins University 2008
- Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine 2003 - 2006
- Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine 2000 - 2003
- M.D., University of Virginia School of Medicine 2000
- B.S.E., Duke University 1996
Duke Appointment History
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2014 - 2018
- Associate Professor in Surgery, Surgery, Urology, Surgery 2017 - 2018
- Associate Professor in Surgery, Surgery, Vascular Surgery, Surgery 2012 - 2017
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2012 - 2014
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2006 - 2011
- Assistant Professor in Surgery, Surgery, Urology, Surgery 2007 - 2011
Recognition
In the News
- JUN 5, 2018 Duke Health News
  
  Tests Identify Who Would Benefit from Advanced Prostate Cancer Therapies
- MAY 26, 2018 Duke Health News
  
  Bone Scan Software Accurately Calculates Prognosis for Advanced Prostate Cancer
- NOV 9, 2015 WRAL
  
  Moustaches fundraise for cancer in 'Movember' movement
- MAY 18, 2015
  
  Duke-led study clarifies best treatments for uncommon kidney cancers
- NOV 19, 2013
  
  Oral Drug May Improve Survival in Men with Metastatic Prostate Cancer
Expertise
Global Scholarship
- Research
- Teaching
  - China (Country)
Research
Selected Grants
- ProSTAR: CPI-1205 awarded by Constellation Pharmaceuticals 2019 - 2024
- VISION PSMA-617-01 awarded by Endocyte, Inc. 2019 - 2024
- A Phase 2 Study of Nivolumab in combination with either Rucaparib, docetaxel, or enzalutamide in men with Castration-resistant metastaic prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMA awarded by Bristol-Myers Squibb Company 2018 - 2023
- MK7123 awarded by Merck Sharp & Dohme 2018 - 2023
- NEPC Trial PD-1 Inhibition in Neuroendocrine-like Prostate Cancer (PD-1 Inhibition or Combination Checkpoint Immuntherapy of Neuroedocrine_Like Prostate Cancer awarded by Pfizer, Inc. 2017 - 2022
- A Phase 1B, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have progressed followinIn awarded by Genentech, Inc. 2017 - 2022
- Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis awarded by Department of Defense 2018 - 2021
- PCRP Clinical Consortium: Duke University Clinical Research Site awarded by Department of Defense 2007 - 2021
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2021
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2021
- GS-5829 mono and combo enzalutamide awarded by Gilead Sciences, Inc. 2016 - 2021
- A Randomized Phase 2 Study of Sipuleucel-T with or without Radium-223 awarded by Johns Hopkins University 2017 - 2021
- Targeting Convergent Mechanisms of Therapy Resistance, Metastasis, and Immune Evasion with CBP inhibitors awarded by FORMA Therapeutics, Inc. 2018 - 2020
- A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc awarded by AstraZeneca Pharmaceuticals, LP 2018 - 2020
- CTC-Immune Checkpoints awarded by Janssen Research & Development, LLC 2016 - 2020
- Pharmacology Industry Internships for Ph.D. Students awarded by American Society for Pharmacology and Experimental Therapeutics 2017 - 2019
- Pharmacodynamic Study of Radium-223 in Men with Bone Metastatic Castration-Resistant Prostate Cancer (CRPC) awarded by Bayer Corporation 2014 - 2019
- A Phase 2 Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuro awarded by Weill Medical College of Cornell University 2013 - 2019
- Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) awarded by Prostate Cancer Foundation 2014 - 2019
- STREAM - Salvage Therapeutic Radiation with Enzalutamide and ADT in Men with Recurrent Prostate Cancer awarded by Astellas Pharma Global Development, Inc 2014 - 2019
- Testing the efficacy of AR degrading compounds in enzalutamide-resistant prostate cancer awarded by Arvinas Inc. 2017 - 2019
- AR variant regulation during EMT and disease progression awarded by National Institutes of Health 2015 - 2018
- A Randomized, Open label, Muiticenter, Phase III, 2 Arm Study of Androgen Deprivation with Leuprilode +/- Docetaxel for awarded by Memorial Sloan Kettering Cancer Center 2013 - 2017
- Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer awarded by National Institutes of Health 2011 - 2016
- Alternative splicing and epithelial-mesenchymal plasticity in prostate tumors awarded by National Institutes of Health 2008 - 2014
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Armstrong, AJ, Halabi, S, Luo, J, Nanus, DM, Giannakakou, P, Szmulewitz, RZ, Danila, DC, Healy, P, Anand, M, Rothwell, CJ, Rasmussen, J, Thornburg, B, Berry, WR, Wilder, RS, Lu, C, Chen, Y, Silberstein, JL, Kemeny, G, Galletti, G, Somarelli, JA, Gupta, S, Gregory, SG, Scher, HI, Dittamore, R, Tagawa, ST, Antonarakis, ES, and George, DJ. "Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 37, no. 13 (May 2019): 1120-1129. Full Text
  - Sonpavde, G, Agarwal, N, Pond, GR, Nagy, RJ, Nussenzveig, RH, Hahn, AW, Sartor, O, Gourdin, TS, Nandagopal, L, Ledet, EM, Naik, G, Armstrong, AJ, Wang, J, Bilen, MA, Gupta, S, Grivas, P, Pal, SK, Lanman, RB, Talasaz, A, and Lilly, MB. "Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer." Cancer 125, no. 9 (May 2019): 1459-1469. Full Text
  - Mota, JM, Armstrong, AJ, Larson, SM, Fox, JJ, and Morris, MJ. "Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials." Prostate Cancer and Prostatic Diseases (April 29, 2019). (Review) Full Text
  - Holl, EK, McNamara, MA, Healy, P, Anand, M, Concepcion, RS, Breland, CD, Dumbudze, I, Tutrone, R, Shore, N, Armstrong, AJ, Harrison, M, Wallace, JA, Wu, Y, and George, DJ. "Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients." Prostate Cancer and Prostatic Diseases (April 12, 2019). Full Text
  - Jolly, MK, Ware, KE, Xu, S, Gilja, S, Shetler, S, Yang, Y, Wang, X, Austin, RG, Runyambo, D, Hish, AJ, Bartholf DeWitt, S, George, JT, Kreulen, RT, Boss, M-K, Lazarides, AL, Kerr, DL, Gerber, DG, Sivaraj, D, Armstrong, AJ, Dewhirst, MW, Eward, WC, Levine, H, and Somarelli, JA. "E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms." Molecular Cancer Research : Mcr (March 12, 2019). Full Text
  - Xu, S, Ware, KE, Ding, Y, Kim, SY, Sheth, MU, Rao, S, Chan, W, Armstrong, AJ, Eward, WC, Jolly, MK, and Somarelli, JA. "An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance." Journal of Clinical Medicine 8, no. 2 (February 7, 2019). Full Text
  - Labriola, MK, Batich, KA, Zhu, J, McNamara, MA, Harrison, MR, Armstrong, AJ, George, DJ, and Zhang, T. "Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma." Clinical Genitourinary Cancer (February 5, 2019). (Review) Full Text
  - Jolly, MK, Somarelli, JA, Sheth, M, Biddle, A, Tripathi, SC, Armstrong, AJ, Hanash, SM, Bapat, SA, Rangarajan, A, and Levine, H. "Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas." Pharmacology & Therapeutics 194 (February 2019): 161-184. (Review) Full Text
  - Zhang, T, George, DJ, and Armstrong, AJ. "Precision Medicine Approaches When Prostate Cancer Akts Up." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 25, no. 3 (February 2019): 901-903. Full Text
  - Beltran, H, Oromendia, C, Danila, DC, Montgomery, B, Hoimes, C, Szmulewitz, RZ, Vaishampayan, U, Armstrong, AJ, Stein, M, Pinski, J, Mosquera, JM, Sailer, V, Bareja, R, Romanel, A, Gumpeni, N, Sboner, A, Dardenne, E, Puca, L, Prandi, D, Rubin, MA, Scher, HI, Rickman, DS, Demichelis, F, Nanus, DM, Ballman, KV, and Tagawa, ST. "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 25, no. 1 (January 2019): 43-51. Full Text
  - Zhang, T, Armstrong, AJ, George, DJ, and Huang, J. "The promise of immunotherapy in genitourinary malignancies." Precision Clinical Medicine 1, no. 3 (December 19, 2018): 97-101. Full Text
  - Armstrong, AJ, Nordle, O, and Morris, M. "Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply." Jama Oncology (December 13, 2018). Full Text
  - Armstrong, AJ, Lin, P, Higano, CS, Sternberg, CN, Sonpavde, G, Tombal, B, Templeton, AJ, Fizazi, K, Phung, D, Wong, EK, Krivoshik, A, and Beer, TM. "Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 11 (November 2018): 2200-2207. Full Text
  - Armstrong, AJ. "Updates in advanced prostate cancer 2018." Prostate Cancer and Prostatic Diseases 21, no. 4 (November 2018): 449-450. Full Text
  - Brown, LC, Sonpavde, G, and Armstrong, AJ. "Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?." Prostate Cancer and Prostatic Diseases 21, no. 3 (September 2018): 419-430. Full Text
  - McNamara, M, Sweeney, C, Antonarakis, ES, and Armstrong, AJ. "The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation." Prostate Cancer and Prostatic Diseases 21, no. 3 (September 2018): 306-318. (Review) Full Text
  - Wu, M, Huang, P-H, Zhang, R, Mao, Z, Chen, C, Kemeny, G, Li, P, Lee, AV, Gyanchandani, R, Armstrong, AJ, Dao, M, Suresh, S, and Huang, TJ. "Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation." Small (Weinheim an Der Bergstrasse, Germany) 14, no. 32 (August 2018): e1801131-null. Full Text
  - Armstrong, Andrew J., Aseem Anand, Lars Edenbrandt, Eva Bondesson, Anders Bjartell, Anders Widmark, Cora N. Sternberg, et al. “Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial..” Jama Oncology 4, no. 7 (July 2018): 944–51. https://doi.org/10.1001/jamaoncol.2018.1093.
    Full Text
  - Fantony, JJ, Howard, LE, Csizmadi, I, Armstrong, AJ, Lark, AL, Galet, C, Aronson, WJ, and Freedland, SJ. "Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study." Biomarkers in Medicine 12, no. 7 (July 2018): 727-736. Full Text
  - Rathkopf, DE, Beer, TM, Loriot, Y, Higano, CS, Armstrong, AJ, Sternberg, CN, de Bono, JS, Tombal, B, Parli, T, Bhattacharya, S, Phung, D, Krivoshik, A, Scher, HI, and Morris, MJ. "Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial." Jama Oncology 4, no. 5 (May 2018): 694-701. Full Text
  - Humeniuk, MS, Gupta, RT, Healy, P, McNamara, M, Ramalingam, S, Harrison, M, George, D, Zhang, T, Wu, Y, and Armstrong, AJ. "Platinum sensitivity in metastatic prostate cancer: does histology matter?." Prostate Cancer and Prostatic Diseases 21, no. 1 (April 2018): 92-99. Full Text
  - Austin, R Garland, Tony Jun Huang, Mengxi Wu, Andrew J. Armstrong, and Tian Zhang. “Clinical utility of non-EpCAM based circulating tumor cell assays..” Advanced Drug Delivery Reviews 125 (February 2018): 132–42. https://doi.org/10.1016/j.addr.2018.01.013.
    Full Text
  - Zhu, Jason, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, and Tian Zhang. “Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond..” Journal for Immunotherapy of Cancer 6, no. 1 (January 25, 2018). https://doi.org/10.1186/s40425-018-0314-1.
    Full Text Open Access Copy
  - Armstrong, AJ, Antonarakis, ES, Taplin, M-E, Kelly, WK, Beltran, H, Fizazi, K, Dahut, WL, Shore, N, Slovin, S, George, D, Carducci, MA, Corn, P, Danila, D, Dreicer, R, Heath, E, Rathkopf, D, Liu, G, Nanus, D, Stein, M, Smith, MR, Sternberg, C, Wilding, G, Nelson, PS, Halabi, S, Kantoff, P, Clarke, NW, Evans, CP, Heidenreich, A, Mottet, N, Gleave, M, Morris, MJ, and Scher, HI. "Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet." Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 23-25. Full Text
  - Taplin, M-E, Armstrong, AJ, Lin, P, Krivoshik, A, Phung, D, Parli, T, Tombal, B, and Beer, TM. "Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo." The Journal of Urology 198, no. 6 (December 2017): 1324-1332. Full Text
  - Zhu, J, Tucker, M, Wang, E, Grossman, JS, Armstrong, AJ, George, DJ, and Zhang, T. "Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer." Clinical Genitourinary Cancer 15, no. 6 (December 2017): e1137-e1141. Full Text Open Access Copy
  - Zhang, Tian, and Andrew J. Armstrong. “The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 28 (October 2017): 3175–77. https://doi.org/10.1200/jco.2017.74.7931.
    Full Text
  - Zhang, T, and Armstrong, AJ. "The who, what, and how of cabazitaxel treatment in metastatic castration-resistant prostate cancer." Journal of Clinical Oncology 35, no. 28 (October 1, 2017): 3175-3177. Full Text
  - Humeniuk, MS, Zhang, T, and Armstrong, AJ. "Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers." Cancer 123, no. 18 (September 2017): 3441-3444. Full Text
  - Humeniuk, MS, and Armstrong, AJ. "RECISTing the Temptation to Prematurely Stop Nivolumab." European Urology 72, no. 3 (September 2017): 377-378. Full Text
  - Armstrong, Andrew J., Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, et al. “Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.” European Journal of Cancer 81 (August 2017): 228–36. https://doi.org/10.1016/j.ejca.2017.02.030.
    Full Text Link to Item
  - Bryce, A. H., J. J. Alumkal, A. Armstrong, C. S. Higano, P. Iversen, C. N. Sternberg, D. Rathkopf, et al. “Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL..” Prostate Cancer and Prostatic Diseases 20, no. 2 (June 2017): 221–27. https://doi.org/10.1038/pcan.2016.71.
    Full Text
  - Armstrong, AJ, Saad, F, Phung, D, Dmuchowski, C, Shore, ND, Fizazi, K, Hirmand, M, Forer, D, Scher, HI, and Bono, JD. "Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel." Cancer 123, no. 12 (June 2017): 2303-2311. Full Text
  - Ramalingam, S, Humeniuk, MS, Hu, R, Rasmussen, J, Healy, P, Wu, Y, Harrison, MR, Armstrong, AJ, George, DJ, and Zhang, T. "Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer." Urol Oncol 35, no. 6 (June 2017): 418-424. Full Text Link to Item
  - Ware, Kathryn E., Shivee Gilja, Shenghan Xu, Samantha Shetler, Mohit K. Jolly, Xueyang Wang, Suzanne Bartholf Dewitt, et al. “Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells..” Journal of Visualized Experiments : Jove, no. 122 (April 7, 2017). https://doi.org/10.3791/55520.
    Full Text
  - Sonpavde, G, and Armstrong, AJ. "Drug development in prostate cancer: time to embrace RECIST?." The Lancet. Oncology 18, no. 4 (April 2017): 419-421. Full Text
  - Armstrong, Andrew J., Michael S. Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R. Harrison, et al. “Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.” Prostate 77, no. 4 (March 1, 2017): 385–95. https://doi.org/10.1002/pros.23277.
    Full Text Link to Item
  - Armstrong, AJ. "Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer." Clinical Advances in Hematology & Oncology : H&O 15, no. 3 (March 2017): 184-188.
  - Gupta, S, Li, J, Kemeny, G, Bitting, RL, Beaver, J, Somarelli, JA, Ware, KE, Gregory, S, and Armstrong, AJ. "Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23, no. 5 (March 2017): 1346-1357. Full Text
  - Beer, Tomasz M., Andrew J. Armstrong, Dana Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, et al. “Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.” European Urology 71, no. 2 (February 2017): 151–54. https://doi.org/10.1016/j.eururo.2016.07.032.
    Full Text Link to Item
  - Penson, DF, Armstrong, AJ, Concepcion, R, Agarwal, N, Olsson, C, Karsh, L, Dunshee, C, Wang, F, Wu, K, Krivoshik, A, Phung, D, and Higano, CS. "Reply to M.A.N. Şendur et al and J. Michels." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 1 (January 2017): 123-null. (Letter) Full Text
  - Ramalingam, S, Eisenberg, A, Foo, WC, Freedman, J, Armstrong, AJ, Moss, LG, and Harrison, MR. "Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome." Int J Urol 23, no. 12 (December 2016): 1038-1041. Full Text Link to Item
  - Armstrong, Andrew J. “Predictive medicine: Using circulating biomarkers to guide management of patients with genitourinary cancers..” Urologic Oncology 34, no. 11 (November 2016): 488–89. https://doi.org/10.1016/j.urolonc.2016.09.009.
    Full Text
  - Evans, Christopher P., Celestia S. Higano, Thomas Keane, Gerald Andriole, Fred Saad, Peter Iversen, Kurt Miller, et al. “The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer..” European Urology 70, no. 4 (October 2016): 675–83. https://doi.org/10.1016/j.eururo.2016.03.017.
    Full Text
  - Somarelli, Jason A., Samantha Shetler, Mohit K. Jolly, Xueyang Wang, Suzanne Bartholf Dewitt, Alexander J. Hish, Shivee Gilja, et al. “Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2..” Molecular and Cellular Biology 36, no. 19 (October 2016): 2503–13. https://doi.org/10.1128/MCB.00373-16.
    Full Text Open Access Copy
  - Antonarakis, ES, Armstrong, AJ, Dehm, SM, and Luo, J. "Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting." Prostate Cancer and Prostatic Diseases 19, no. 3 (September 2016): 231-241. (Review) Full Text
  - Shields Iv, CW, Wang, JL, Ohiri, KA, Essoyan, ED, Yellen, BB, Armstrong, AJ, and López, GP. "Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis." Lab on a Chip 16, no. 19 (September 2016): 3833-3844. Full Text
  - Somarelli, J. A., D. Schaeffer, M. S. Marengo, T. Bepler, D. Rouse, K. E. Ware, A. J. Hish, et al. “Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways..” Oncogene 35, no. 33 (August 2016): 4302–11. https://doi.org/10.1038/onc.2015.497.
    Full Text Open Access Copy
  - Ware, Kathryn E., Jason A. Somarelli, Daneen Schaeffer, Jing Li, Tian Zhang, Sally Park, Steven R. Patierno, et al. “Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer..” Oncotarget 7, no. 31 (August 2016): 50507–21. https://doi.org/10.18632/oncotarget.10476.
    Full Text Open Access Copy
  - Penson, DF, Armstrong, AJ, Concepcion, R, Agarwal, N, Olsson, C, Karsh, L, Dunshee, C, Wang, F, Wu, K, Krivoshik, A, Phung, D, and Higano, CS. "Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 18 (June 2016): 2098-2106. Full Text
  - Sonpavde, G, Pond, GR, Templeton, AJ, Fandi, A, Tombal, B, Rosenthal, M, Armstrong, AJ, and Petrylak, DP. "Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel." European Urology 69, no. 6 (June 2016): 980-983. Full Text
  - Zhang, T, Boominathan, R, Foulk, B, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, Hsu, DS, Healy, P, Li, J, Pi, C, Prendergast, KM, Hobbs, C, Gemberling, S, George, DJ, Hurwitz, HI, Connelly, M, Garcia-Blanco, MA, and Armstrong, AJ. "Development of a Novel c-MET-Based CTC Detection Platform." Mol Cancer Res 14, no. 6 (June 2016): 539-547. Full Text Open Access Copy Link to Item
  - Ramalingam, S, Sermer, DJ, Gupta, R, Healy, P, Wu, Y, George, DJ, Armstrong, AJ, and Harrison, MR. "Changes in skeletal muscle cross sectional area (CSA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZ)." Journal of Clinical Oncology 34, no. 15_suppl (May 20, 2016): e16601-e16601. Full Text
  - Halabi, S, Kelly, WK, Ma, H, Zhou, H, Solomon, NC, Fizazi, K, Tangen, CM, Rosenthal, M, Petrylak, DP, Hussain, M, Vogelzang, NJ, Thompson, IM, Chi, KN, de Bono, J, Armstrong, AJ, Eisenberger, MA, Fandi, A, Li, S, Araujo, JC, Logothetis, CJ, Quinn, DI, Morris, MJ, Higano, CS, Tannock, IF, and Small, EJ. "Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 14 (May 2016): 1652-1659. Full Text
  - Scher, HI, Morris, MJ, Stadler, WM, Higano, C, Basch, E, Fizazi, K, Antonarakis, ES, Beer, TM, Carducci, MA, Chi, KN, Corn, PG, de Bono, JS, Dreicer, R, George, DJ, Heath, EI, Hussain, M, Kelly, WK, Liu, G, Logothetis, C, Nanus, D, Stein, MN, Rathkopf, DE, Slovin, SF, Ryan, CJ, Sartor, O, Small, EJ, Smith, MR, Sternberg, CN, Taplin, M-E, Wilding, G, Nelson, PS, Schwartz, LH, Halabi, S, Kantoff, PW, Armstrong, AJ, and Prostate Cancer Clinical Trials Working Group 3, . "Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 12 (April 2016): 1402-1418. Full Text
  - Armstrong, A. J., P. Healy, S. Halabi, R. Vollmer, A. Lark, G. Kemeny, K. Ware, and S. J. Freedland. “Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer..” Prostate Cancer and Prostatic Diseases 19, no. 1 (March 2016): 40–45. https://doi.org/10.1038/pcan.2015.46.
    Full Text Open Access Copy
  - Armstrong, A. J., S. Halabi, P. Healy, W. R. Lee, B. F. Koontz, J. W. Moul, K. Mundy, et al. “A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.” Prostate Cancer and Prostatic Diseases 19, no. 1 (March 2016): 100–106. https://doi.org/10.1038/pcan.2015.59.
    Full Text Link to Item
  - Armstrong, AJ, Halabi, S, Eisen, T, Broderick, S, Stadler, WM, Jones, RJ, Garcia, JA, Vaishampayan, UN, Picus, J, Hawkins, RE, Hainsworth, JD, Kollmannsberger, CK, Logan, TF, Puzanov, I, Pickering, LM, Ryan, CW, Protheroe, A, Lusk, CM, Oberg, S, and George, DJ. "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial." The Lancet. Oncology 17, no. 3 (March 2016): 378-388. Full Text
  - Graff, J. N., G. Baciarello, A. J. Armstrong, C. S. Higano, P. Iversen, T. W. Flaig, D. Forer, et al. “Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 27, no. 2 (February 2016): 286–94. https://doi.org/10.1093/annonc/mdv542.
    Full Text
  - Tay, Kae Jack, Judd W. Moul, and Andrew J. Armstrong. “Management of Prostate Cancer in the Elderly..” Clinics in Geriatric Medicine 32, no. 1 (February 2016): 113–32. https://doi.org/10.1016/j.cger.2015.08.001.
    Full Text
  - Mehta, AR, and Armstrong, AJ. "Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects." Therapeutic Advances in Urology 8, no. 1 (February 2016): 9-18. (Review) Full Text
  - Mohler, James L., Andrew J. Armstrong, Robert R. Bahnson, Anthony Victor D’Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, et al. “Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines.” Journal of the National Comprehensive Cancer Network 14, no. 1 (January 2016): 19–30. https://doi.org/10.6004/jnccn.2016.0004.
    Full Text Link to Item
  - Zhang, Tian, and Andrew J. Armstrong. “Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer..” Current Oncology Reports 18, no. 1 (January 2016). https://doi.org/10.1007/s11912-015-0490-9.
    Full Text
  - Mohler, JL, Armstrong, AJ, Bahnson, RR, D'Amico, AV, Davis, BJ, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Hurwitz, M, Kane, CJ, Kawachi, MH, Kuettel, M, Lee, RJ, Meeks, JJ, Penson, DF, Plimack, ER, Pow-Sang, JM, Raben, D, Richey, S, Roach, M, Rosenfeld, S, Schaeffer, E, Skolarus, TA, Small, EJ, Sonpavde, G, Srinivas, S, Strope, SA, Tward, J, Shead, DA, and Freedman-Cass, DA. "Prostate Cancer, Version 1.2016." Journal of the National Comprehensive Cancer Network : Jnccn 14, no. 1 (January 2016): 19-30. Full Text
  - Zhang, Tian, and Andrew J. Armstrong. “Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 21, no. 20 (October 2015): 4505–7. https://doi.org/10.1158/1078-0432.ccr-15-1613.
    Full Text Open Access Copy
  - Hussain, M, Rathkopf, D, Liu, G, Armstrong, A, Kelly, WK, Ferrari, A, Hainsworth, J, Joshi, A, Hozak, RR, Yang, L, Schwartz, JD, and Higano, CS. "A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer." European Journal of Cancer (Oxford, England : 1990) 51, no. 13 (September 2015): 1714-1724. Full Text
  - Kanesvaran, R, Watt, K, Turnbull, JD, Armstrong, AJ, Wolkowiez, MC, and George, DJ. "A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma." Clinical Genitourinary Cancer 13, no. 4 (August 2015): 319-327. Full Text
  - Zhang, T, Dhawan, MS, Healy, P, George, DJ, Harrison, MR, Oldan, J, Chin, B, and Armstrong, AJ. "Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer." Clin Genitourin Cancer 13, no. 4 (August 2015): 392-399. Full Text Link to Item
  - Armstrong, Andrew J. “Docetaxel for advanced prostate cancer: how early to start?.” The Lancet. Oncology 16, no. 7 (July 2015): 741–42. https://doi.org/10.1016/s1470-2045(15)00012-1.
    Full Text
  - Sonpavde, G, Wang, CG, Galsky, MD, Oh, WK, and Armstrong, AJ. "Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)." Bju International 116, no. 1 (July 2015): 17-29. (Review) Full Text
  - Somarelli, Jason A., Mary-Keara Boss, Jonathan I. Epstein, Andrew J. Armstrong, and Mariano A. Garcia-Blanco. “Carcinosarcomas: tumors in transition?.” Histology and Histopathology 30, no. 6 (June 2015): 673–87. https://doi.org/10.14670/hh-30.673.
    Full Text
  - Davis, K, Wood, S, Dill, E, Fesko, Y, Bitting, RL, Harrison, MR, Armstrong, AJ, Moul, JW, and George, DJ. "Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution." Clin J Oncol Nurs 19, no. 3 (June 2015): 297-303. Full Text Link to Item
  - Stover, JT, Moore, RA, Davis, K, Harrison, MR, and Armstrong, AJ. "Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer." Prostate Cancer and Prostatic Diseases 18, no. 2 (June 2015): 161-166. Full Text
  - Armstrong, Andrew J. “New Treatment Options in Castration-Resistant Prostate Cancer.” Journal of the National Comprehensive Cancer Network 13, no. 5.5 (May 2015): 690–93. https://doi.org/10.6004/jnccn.2015.0205.
    Full Text Link to Item
  - Armstrong, AJ. "New treatment options in castration-resistant prostate cancer." Journal of the National Comprehensive Cancer Network : Jnccn 13, no. 5 Suppl (May 2015): 690-693. Full Text
  - Li, J, and Armstrong, AJ. "Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer." Clinical Advances in Hematology & Oncology : H&O 13, no. 5 (May 2015): 293-298.
  - Armstrong, Andrew J., and Susan Halabi. “Making progress on progression in metastatic prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 12 (April 2015): 1322–24. https://doi.org/10.1200/jco.2014.59.4283.
    Full Text
  - Bitting, Rhonda L., Patrick Healy, Susan Halabi, Daniel J. George, Michael Goodin, and Andrew J. Armstrong. “Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer..” Urologic Oncology 33, no. 3 (March 2015): 110.e1-110.e9. https://doi.org/10.1016/j.urolonc.2014.09.002.
    Full Text
  - Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew J. Armstrong. “Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer..” Expert Opinion on Pharmacotherapy 16, no. 4 (March 2015): 473–85. https://doi.org/10.1517/14656566.2015.995090.
    Full Text
  - Bitting, RL, Healy, P, Halabi, S, George, DJ, Goodin, M, and Armstrong, AJ. "Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer." Urologic Oncology: Seminars and Original Investigations 33, no. 3 (March 1, 2015): 110.e1-110.e9. Full Text
  - Harrison, MR, and Armstrong, AJ. "Burden of disease matters when it comes to systemic therapy for prostate cancer." European Urology 67, no. 3 (March 2015): 448-450. Full Text
  - Harrison, MR, and Armstrong, AJ. "Burden of disease matters when it comes to systemic therapy for prostate cancer." European Urology 67, no. 3 (March 1, 2015): 448-450. Full Text
  - Li, Jing, Simon G. Gregory, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Using circulating tumor cells to inform on prostate cancer biology and clinical utility..” Critical Reviews in Clinical Laboratory Sciences 52, no. 4 (January 2015): 191–210. https://doi.org/10.3109/10408363.2015.1023430.
    Full Text
  - Shuch, Brian, Ali Amin, Andrew J. Armstrong, John N. Eble, Vincenzo Ficarra, Antonio Lopez-Beltran, Guido Martignoni, Brian I. Rini, and Alexander Kutikov. “Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity..” European Urology 67, no. 1 (January 2015): 85–97. https://doi.org/10.1016/j.eururo.2014.04.029.
    Full Text
  - Shuch, B, Amin, A, Armstrong, AJ, Eble, JN, Ficarra, V, Lopez-Beltran, A, Martignoni, G, Rini, BI, and Kutikov, A. "Understanding pathologic variants of renal cell carcinoma: Distilling therapeutic opportunities from biologic complexity." European Urology 67, no. 1 (January 1, 2015): 85-97. (Review) Full Text
  - Stewart, Suzanne B., Judd W. Moul, Thomas J. Polascik, Bridget F. Koontz, Cary N. Robertson, Stephen J. Freedland, Daniel J. George, W Robert Lee, Andrew J. Armstrong, and Lionel L. Bañez. “Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?.” International Journal of Urology : Official Journal of the Japanese Urological Association 21, no. 12 (December 2014): 1215–19. https://doi.org/10.1111/iju.12561.
    Full Text
  - Sonpavde, G, Pond, GR, Armstrong, AJ, Galsky, MD, Leopold, L, Wood, BA, Wang, S-L, Paolini, J, Chen, I, Chow-Maneval, E, Mooney, DJ, Lechuga, M, Smith, MR, and Michaelson, MD. "Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer." Bju International 114, no. 6b (December 2014): E25-E31. Full Text
  - Armstrong, AJ, Kaboteh, R, Carducci, MA, Damber, J-E, Stadler, WM, Hansen, M, Edenbrandt, L, Forsberg, G, Nordle, Ö, Pili, R, and Morris, MJ. "Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)." Urologic Oncology 32, no. 8 (November 2014): 1308-1316. Full Text
  - Armstrong, A. J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park, N.Y.) 28, no. 10 (October 1, 2014).
  - Armstrong, AJ. "In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet." Oncology (Williston Park, N.Y.) 28, no. 10 (October 2014): 881-883.
  - Sonpavde, G, Pond, GR, Armstrong, AJ, Clarke, SJ, Vardy, JL, Templeton, AJ, Wang, S-L, Paolini, J, Chen, I, Chow-Maneval, E, Lechuga, M, Smith, MR, and Michaelson, MD. "Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer." Clinical Genitourinary Cancer 12, no. 5 (October 2014): 317-324. Full Text
  - Bitting, Rhonda L., Daneen Schaeffer, Jason A. Somarelli, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “The role of epithelial plasticity in prostate cancer dissemination and treatment resistance..” Cancer Metastasis Reviews 33, no. 2–3 (September 2014): 441–68. https://doi.org/10.1007/s10555-013-9483-z.
    Full Text
  - Halabi, S., H. Zhou, E. J. Small, N. C. Solomon, A. J. Armstrong, L. Shen, S. Oudard, O. Sartor, and J. S. de Bono. “795PA PROGNOSTIC MODEL FOR PREDICTING RADIOGRAPHIC PROGRESSION- FREE SURVIVAL (RPFS) IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER MEN TREATED WITH SECOND-LINE CHEMOTHERAPY..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 25, no. suppl_4 (September 2014).
  - Bitting, Rhonda L., Patrick Healy, Patricia A. Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I. Hurwitz, et al. “A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma..” Clinical Genitourinary Cancer 12, no. 4 (August 2014): 241–50. https://doi.org/10.1016/j.clgc.2013.11.020.
    Full Text
  - Ware, Kathryn E., Mariano A. Garcia-Blanco, Andrew J. Armstrong, and Scott M. Dehm. “Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer..” Endocrine Related Cancer 21, no. 4 (August 2014): T87–103. https://doi.org/10.1530/ERC-13-0470.
    Full Text
  - Beer, TM, Armstrong, AJ, Rathkopf, DE, Loriot, Y, Sternberg, CN, Higano, CS, Iversen, P, Bhattacharya, S, Carles, J, Chowdhury, S, Davis, ID, de Bono, JS, Evans, CP, Fizazi, K, Joshua, AM, Kim, C-S, Kimura, G, Mainwaring, P, Mansbach, H, Miller, K, Noonberg, SB, Perabo, F, Phung, D, Saad, F, Scher, HI, Taplin, M-E, Venner, PM, Tombal, B, and PREVAIL Investigators, . "Enzalutamide in metastatic prostate cancer before chemotherapy." The New England Journal of Medicine 371, no. 5 (July 2014): 424-433. Full Text
  - Mohler, James L., Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, et al. “Prostate cancer, version 2.2014..” Journal of the National Comprehensive Cancer Network : Jnccn 12, no. 5 (May 2014): 686–718. https://doi.org/10.6004/jnccn.2014.0072.
    Full Text
  - Aggarwal, R, Zhang, T, Small, EJ, and Armstrong, AJ. "Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes." Journal of the National Comprehensive Cancer Network : Jnccn 12, no. 5 (May 2014): 719-726. (Review) Full Text
  - Younis, IR, George, DJ, McManus, TJ, Hurwitz, H, Creel, P, Armstrong, AJ, Yu, JJ, Bacon, K, Hobbs, G, Peer, CJ, and Petros, WP. "Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer." Cancer Chemotherapy and Pharmacology 73, no. 5 (May 2014): 991-997. Full Text
  - Armstrong, A. J. “Biomarkers in castration-resistant prostate cancer.” Clinical Advances in Hematology and Oncology 12, no. 2 (February 1, 2014): 115–18.
  - Armstrong, Andrew J. “Biomarkers in castration-resistant prostate cancer..” Clinical Advances in Hematology & Oncology : H&O 12, no. 2 (February 2014): 115–18.
  - Armstrong, Andrew J. “New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?.” European Urology 65, no. 2 (February 2014): 300–302. https://doi.org/10.1016/j.eururo.2013.08.059.
    Full Text
  - Armstrong, AJ. "New treatments for men with castration-resistant prostate cancer: Can we move from small steps to giant leaps?." European Urology 65, no. 2 (February 1, 2014): 300-302. Full Text
  - "The role of epithelial plasticity in prostate cancer dissemination and treatment resistance." Cancer and Metastasis Reviews 33, no. 2-3 (January 1, 2014): 441-468. Full Text
  - "Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work." Urologic Oncology: Seminars and Original Investigations 32, no. 8 (January 1, 2014): 1308-1316. Full Text
  - Pond, Gregory R., Guru Sonpavde, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, and Andrew J. Armstrong. “The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer..” European Urology 65, no. 1 (January 2014): 3–6. https://doi.org/10.1016/j.eururo.2013.09.024.
    Full Text
  - Bitting, RL, Healy, P, Creel, PA, Turnbull, J, Morris, K, Wood, SY, Hurwitz, HI, Starr, MD, Nixon, AB, Armstrong, AJ, and George, DJ. "A phase Ib study of combined VEGFR and mTOR inhibition with Vatalanib and everolimus in patients with advanced renal cell carcinoma." Clinical Genitourinary Cancer 12, no. 4 (January 1, 2014): 241-250. Full Text
  - Mohler, JL, Kantoff, PW, Armstrong, AJ, Bahnson, RR, Cohen, M, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Kane, CJ, Kawachi, MH, Kuettel, M, Kuzel, TM, Lee, RJ, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, Raben, D, Richey, S, Roach, M, Rohren, E, Rosenfeld, S, Schaeffer, E, Small, EJ, Sonpavde, G, Srinivas, S, Stein, C, Strope, SA, Tward, J, Shead, DA, and Ho, M. "Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology." Jnccn Journal of the National Comprehensive Cancer Network 12, no. 5 (January 1, 2014): 686-718. (Review) Full Text
  - Pond, GR, Sonpavde, G, De Wit, R, Eisenberger, MA, Tannock, IF, and Armstrong, AJ. "The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer." European Urology 65, no. 1 (January 1, 2014): 3-6. Full Text
  - Sonpavde, G, Pond, GR, Armstrong, AJ, Clarke, SJ, Vardy, JL, Templeton, AJ, Wang, SL, Paolini, J, Chen, I, Chow-Maneval, E, Lechuga, M, Smith, MR, and Dror Michaelson, M. "Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer." Clinical Genitourinary Cancer 12, no. 5 (January 1, 2014): 317-324. Full Text
  - Stewart, SB, Moul, JW, Polascik, TJ, Koontz, BF, Robertson, CN, Freedland, SJ, George, DJ, Lee, WR, Armstrong, AJ, and Bañez, LL. "Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?." International Journal of Urology 21, no. 12 (January 1, 2014): 1215-1219. Full Text
  - Younis, IR, George, DJ, McManus, TJ, Hurwitz, H, Creel, P, Armstrong, AJ, Yu, JJ, Bacon, K, Hobbs, G, Peer, CJ, and Petros, WP. "Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer." Cancer Chemotherapy and Pharmacology 73, no. 5 (January 1, 2014): 991-997. Full Text
  - Armstrong, A. J., M. Häggman, W. M. Stadler, J. R. Gingrich, V. Assikis, J. Polikoff, J. E. Damber, et al. “Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 19, no. 24 (December 2013): 6891–6901. https://doi.org/10.1158/1078-0432.CCR-13-1581.
    Full Text
  - Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda L. Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer..” Clinical Genitourinary Cancer 11, no. 4 (December 2013): 397–406. https://doi.org/10.1016/j.clgc.2013.05.007.
    Full Text
  - Mohler, James L., Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, et al. “Prostate cancer, version 1.2014..” Journal of the National Comprehensive Cancer Network : Jnccn 11, no. 12 (December 2013): 1471–79. https://doi.org/10.6004/jnccn.2013.0174.
    Full Text
  - Schweizer, M. T., J. Lin, A. Blackford, A. Bardia, S. King, A. J. Armstrong, M. A. Rudek, S. Yegnasubramanian, and M. A. Carducci. “Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer..” Prostate Cancer and Prostatic Diseases 16, no. 4 (December 2013): 357–61. https://doi.org/10.1038/pcan.2013.28.
    Full Text
  - Stoyanova, Tanya, Aaron R. Cooper, Justin M. Drake, Xian Liu, Andrew J. Armstrong, Kenneth J. Pienta, Hong Zhang, et al. “Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells..” Proceedings of the National Academy of Sciences of the United States of America 110, no. 50 (December 2013): 20111–16. https://doi.org/10.1073/pnas.1320565110.
    Full Text
  - Araujo, JC, Trudel, GC, Saad, F, Armstrong, AJ, Yu, EY, Bellmunt, J, Wilding, G, McCaffrey, J, Serrano, SV, Matveev, VB, Efstathiou, E, Oudard, S, Morris, MJ, Sizer, B, Goebell, PJ, Heidenreich, A, de Bono, JS, Begbie, S, Hong, JH, Richardet, E, Gallardo, E, Paliwal, P, Durham, S, Cheng, S, and Logothetis, CJ. "Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial." The Lancet Oncology 14, no. 13 (December 1, 2013): 1307-1316. Full Text
  - Araujo, JC, Trudel, GC, Saad, F, Armstrong, AJ, Yu, EY, Bellmunt, J, Wilding, G, McCaffrey, J, Serrano, SV, Matveev, VB, Efstathiou, E, Oudard, S, Morris, MJ, Sizer, B, Goebell, PJ, Heidenreich, A, de Bono, JS, Begbie, S, Hong, JH, Richardet, E, Gallardo, E, Paliwal, P, Durham, S, Cheng, S, and Logothetis, CJ. "Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial." The Lancet. Oncology 14, no. 13 (December 2013): 1307-1316. Full Text
  - Armstrong, AJ, Shen, T, Halabi, S, Kemeny, G, Bitting, RL, Kartcheske, P, Embree, E, Morris, K, Winters, C, Jaffe, T, Fleming, M, and George, DJ. "A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer." Clinical Genitourinary Cancer 11, no. 4 (December 1, 2013): 397-406. Full Text
  - Bitting, RL, Boominathan, R, Rao, C, Kemeny, G, Foulk, B, Garcia-Blanco, MA, Connelly, M, and Armstrong, AJ. "Development of a method to isolate circulating tumor cells using mesenchymal-based capture." Methods 64, no. 2 (December 1, 2013): 129-136. Full Text
  - Bitting, RL, Boominathan, R, Rao, C, Kemeny, G, Foulk, B, Garcia-Blanco, MA, Connelly, M, and Armstrong, AJ. "Development of a method to isolate circulating tumor cells using mesenchymal-based capture." Methods (San Diego, Calif.) 64, no. 2 (December 2013): 129-136. Full Text
  - Schweizer, MT, Lin, J, Blackford, A, Bardia, A, King, S, Armstrong, AJ, Rudek, MA, Yegnasubramanian, S, and Carducci, MA. "Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer." Prostate Cancer and Prostatic Diseases 16, no. 4 (December 1, 2013): 357-361. Full Text
  - Halabi, Susan, Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Ellen Kaplan, Chen-Yen Lin, Nicole C. Solomon, and Eric J. Small. “Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 31 (November 2013): 3944–50. https://doi.org/10.1200/JCO.2013.50.3201.
    Full Text
  - Zhang, Tian, and Andrew J. Armstrong. “Clinical phenotypes of castration-resistant prostate cancer..” Clinical Advances in Hematology & Oncology : H&O 11, no. 11 (November 2013): 707–18.
  - Armstrong, AJ, Galsky, MD, Wood, BA, Leopold, L, and Sonpavde, G. "Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials." Urologic Oncology: Seminars and Original Investigations 31, no. 8 (November 1, 2013): 1457-1463. Full Text
  - Halabi, S, Lin, C-Y, Small, EJ, Armstrong, AJ, Kaplan, EB, Petrylak, D, Sternberg, CN, Shen, L, Oudard, S, de Bono, J, and Sartor, O. "Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy." Journal of the National Cancer Institute 105, no. 22 (November 2013): 1729-1737. Full Text
  - Pond, GR, Armstrong, AJ, Galsky, MD, Wood, BA, Leopold, L, and Sonpavde, G. "Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials." Urologic Oncology 31, no. 8 (November 2013): 1457-1463. Full Text
  - Peppercorn, Jeffrey, Andrew Armstrong, David W. Zaas, and Daniel George. “Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer..” Urologic Oncology 31, no. 7 (October 2013): 1079–84. https://doi.org/10.1016/j.urolonc.2011.12.022.
    Full Text
  - George, Daniel J., Andrew J. Armstrong, and Michael R. Harrison. “Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary..” Clin Adv Hematol Oncol 11 Suppl 14, no. 9 (September 2013): 16–22.
    Link to Item
  - Noonan, KL, North, S, Bitting, RL, Armstrong, AJ, Ellard, SL, and Chi, KN. "Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide." Annals of Oncology : Official Journal of the European Society for Medical Oncology 24, no. 7 (July 2013): 1802-1807. Full Text
  - Bitting, Rhonda L., and Andrew J. Armstrong. “Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer..” Endocrine Related Cancer 20, no. 3 (June 2013): R83–99. https://doi.org/10.1530/erc-12-0394.
    Full Text
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Reply to M A Khattak et al..” J Clin Oncol 31, no. 7 (March 1, 2013): 972–73. https://doi.org/10.1200/JCO.2012.47.7224.
    Full Text Link to Item
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Reply to M A Khattak et al..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 7 (March 2013): 972–73. https://doi.org/10.1200/jco.2012.47.7224.
    Full Text
  - Clarke, J. M., and A. J. Armstrong. “Novel therapies for the treatment of advanced prostate cancer..” Current Treatment Options in Oncology 14, no. 1 (March 2013): 109–26. https://doi.org/10.1007/s11864-012-0222-4.
    Full Text
  - Turnbull, James D., Julien Cobert, Tracy Jaffe, Michael R. Harrison, Daniel J. George, and Andrew J. Armstrong. “Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors..” Clinical Genitourinary Cancer 11, no. 1 (March 2013): 45–50. https://doi.org/10.1016/j.clgc.2012.06.001.
    Full Text
  - Khazanie, P, and Granger, CB. "Commentary." Annals of Internal Medicine 158, no. 4 (February 19, 2013).
  - Bardia, A., A. L. Blackford, J. Lin, A. J. Armstrong, S. King, M. A. Rudek, S. T. Yegnasubramanian, and M. A. Carducci. “A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013).
  - Fizazi, K., F. Saad, K. N. Chi, M. E. Taplin, C. N. Sternberg, A. J. Armstrong, M. Hirmand, D. Forer, and J. S. De Bono. “Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013).
  - Lin, C. Y., E. J. Small, A. J. Armstrong, E. B. Kaplan, D. P. Petrylak, C. N. Sternberg, L. Shen, S. Oudard, J. S. De Bono, and A. O. Sartor. “A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013).
  - Trudel, G. C., F. Saad, A. J. Armstrong, E. Y. Yu, J. Bellmunt, G. Wilding, J. McCaffrey, et al. “Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013).
  - Saylor, PJ, Armstrong, AJ, Fizazi, K, Freedland, S, Saad, F, Smith, MR, Tombal, B, and Pienta, K. "New and emerging therapies for bone metastases in genitourinary cancers." European Urology 63, no. 2 (February 2013): 309-320. (Review) Full Text
  - Harrison, MR, Wong, TZ, Armstrong, AJ, and George, DJ. "Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease." Cancer Management and Research 5 (January 8, 2013): 1-14. Full Text
  - Bitting, Rhonda L., and Andrew J. Armstrong. “Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer..” Cancer Journal (Sudbury, Mass.) 19, no. 1 (January 2013): 25–33. https://doi.org/10.1097/ppo.0b013e31827e0b9c.
    Full Text
  - Peppercorn, J., A. Armstrong, D. W. Zaas, and D. George. “Rationing in urologic oncology: Lessons from sipuleucel-T for advanced prostate cancer.” Urologic Oncology: Seminars and Original Investigations 31, no. 7 (2013): 1079–84. https://doi.org/10.1016/j.urolonc.2011.12.022.
    Full Text
  - Saylor, P. J., A. J. Armstrong, K. Fizazi, S. Freedland, F. Saad, M. R. Smith, B. Tombal, and K. Pienta. “New and emerging therapies for bone metastases in genitourinary cancers.” European Urology 63, no. 2 (2013): 309–20. https://doi.org/10.1016/j.eururo.2012.10.007.
    Full Text
  - Whang, Y. E., A. J. Armstrong, W. K. Rathmell, P. A. Godley, W. Y. Kim, R. S. Pruthi, E. M. Wallen, et al. “A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.” Urologic Oncology: Seminars and Original Investigations 31, no. 1 (2013): 82–86. https://doi.org/10.1016/j.urolonc.2010.09.018.
    Full Text
  - Whang, YE, Armstrong, AJ, Rathmell, WK, Godley, PA, Kim, WY, Pruthi, RS, Wallen, EM, Crane, JM, Moore, DT, Grigson, G, Morris, K, Watkins, CP, and George, DJ. "A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer." Urologic Oncology 31, no. 1 (January 2013): 82-86. Full Text
  - Pond, GR, Armstrong, AJ, Wood, BA, Leopold, L, Galsky, MD, and Sonpavde, G. "Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy." Bju International 110, no. 11 Pt B (December 2012): E461-E468. Full Text
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 27 (September 2012): 3402–7. https://doi.org/10.1200/jco.2011.40.9631.
    Full Text
  - Mohler, JL, Armstrong, AJ, Bahnson, RR, Boston, B, Busby, JE, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, T, Higano, CS, Horwitz, EM, Kantoff, PW, Kawachi, MH, Kuettel, M, Lee, RJ, MacVicar, GR, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, Roach, M, Rohren, E, Rosenfeld, S, Srinivas, S, Strope, SA, Tward, J, Twardowski, P, Walsh, PC, Ho, M, and Shead, DA. "Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines." Journal of the National Comprehensive Cancer Network : Jnccn 10, no. 9 (September 2012): 1081-1087. Full Text
  - Scher, HI, Fizazi, K, Saad, F, Taplin, M-E, Sternberg, CN, Miller, K, de Wit, R, Mulders, P, Chi, KN, Shore, ND, Armstrong, AJ, Flaig, TW, Fléchon, A, Mainwaring, P, Fleming, M, Hainsworth, JD, Hirmand, M, Selby, B, Seely, L, de Bono, JS, and AFFIRM Investigators, . "Increased survival with enzalutamide in prostate cancer after chemotherapy." The New England Journal of Medicine 367, no. 13 (September 2012): 1187-1197. Full Text
  - Sonpavde, G, Pond, GR, Berry, WR, de Wit, R, Armstrong, AJ, Eisenberger, MA, and Tannock, IF. "Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy." Urologic Oncology 30, no. 5 (September 2012): 607-613. Full Text
  - Armstrong, AJ. "Where does abiraterone fit into the metastatic prostate cancer treatment algorithm?." Community Oncology 9, no. 8 (August 1, 2012): 238-239. Full Text
  - Sonpavde, Guru, and Andrew J. Armstrong. “Objective evaluation of bone metastases in prostate cancer: to what end?.” European Urology 62, no. 1 (July 2012): 85–87. https://doi.org/10.1016/j.eururo.2012.02.021.
    Full Text
  - Armstrong, Andrew J. “The STAMPEDE trial and celecoxib: how to adapt?.” The Lancet. Oncology 13, no. 5 (May 2012): 443–45. https://doi.org/10.1016/s1470-2045(12)70111-0.
    Full Text
  - Armstrong, Andrew J., Mario A. Eisenberger, Susan Halabi, Stephane Oudard, David M. Nanus, Daniel P. Petrylak, A Oliver Sartor, and Howard I. Scher. “Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer..” European Urology 61, no. 3 (March 2012): 549–59. https://doi.org/10.1016/j.eururo.2011.11.009.
    Full Text
  - Sandilos, Joanna K., Yu-Hsin Chiu, Faraaz B. Chekeni, Allison J. Armstrong, Scott F. Walk, Kodi S. Ravichandran, and Douglas A. Bayliss. “Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associated C-terminal autoinhibitory region..” The Journal of Biological Chemistry 287, no. 14 (March 2012): 11303–11. https://doi.org/10.1074/jbc.M111.323378.
    Full Text
  - Armstrong, A. J., J. D. Turnbull, J. Cobert, T. Jaffe, M. R. Harrison, and D. J. George. “Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies..” J Clin Oncol 30, no. 5_suppl (February 10, 2012). https://doi.org/10.1200/jco.2012.30.5_suppl.435.
    Full Text Link to Item
  - Hussain, Maha, Dana E. Rathkopf, Glenn Liu, Andrew J. Armstrong, William Kevin Kelly, Anna C. Ferrari, John D. Hainsworth, Ling Yang, Jonathan D. Schwartz, and Celestia S. Higano. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy..” Journal of Clinical Oncology 30, no. 5 (February 10, 2012). https://doi.org/10.1200/jco.2012.30.5_suppl.97.
    Full Text Link to Item
  - Pond, Gregory Russell, Andrew J. Armstrong, Brian A. Wood, Lance Howard Leopold, Matt D. Galsky, and Guru Sonpavde. “Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)..” Journal of Clinical Oncology 30, no. 5 (February 10, 2012). https://doi.org/10.1200/jco.2012.30.5_suppl.204.
    Full Text Link to Item
  - Armstrong, A. J., J. D. Turnbull, J. Cobert, T. Jaffe, M. R. Harrison, and D. J. George. “Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Armstrong, A. J., J. R. Gingrich, M. Haggman, W. M. Stadler, J. E. Damber, L. Belkoff, R. Clark, et al. “Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer.” European Urology Supplements 11, no. 1 (February 1, 2012): E126-U515.
    Link to Item
  - Hussain, M., D. E. Rathkopf, G. Liu, A. J. Armstrong, W. K. Kelly, A. C. Ferrari, J. D. Hainsworth, L. Yang, J. D. Schwartz, and C. S. Higano. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Hussain, M., D. E. Rathkopf, G. Liu, A. J. Armstrong, W. K. Kelly, A. C. Ferrari, J. D. Hainsworth, L. Yang, J. D. Schwartz, and C. S. Higano. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Pond, G. R., A. J. Armstrong, B. A. Wood, L. H. Leopold, M. D. Galsky, and G. Sonpavde. “Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Pond, G. R., A. J. Armstrong, B. A. Wood, L. H. Leopold, M. D. Galsky, and G. Sonpavde. “Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Armstrong, AJ, Turnbull, JD, Cobert, J, Jaffe, T, Harrison, MR, and George, DJ. "Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012): 435-.
  - Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, L, Berry, WR, de Wit, R, Eisenberger, MA, Tannock, IF, and Sonpavde, G. "Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer." European Urology 61, no. 2 (February 2012): 363-369. Full Text
  - Sonpavde, G, Pond, GR, and Armstrong, AJ. "Reply to YiJun Shen and DingWei Ye's letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9." European Urology 61, no. 2 (February 1, 2012). (Letter) Full Text
  - Armstrong, A. J., J. W. Moul, and D. J. George. “What to order from the prostate cancer treatment menu?.” Oncology (Williston Park, N.Y.) 26, no. 1 (January 1, 2012).
  - Pond, G. R., A. J. Armstrong, B. A. Wood, L. Leopold, M. D. Galsky, and G. Sonpavde. “Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.” Bju International 110, no. 11 B (2012): E461–68. https://doi.org/10.1111/j.1464-410X.2012.11148.x.
    Full Text
  - Stewart, Suzanne Biehn, Lionel L. Bañez, Cary N. Robertson, Stephen J. Freedland, Thomas J. Polascik, Donghua Xie, Bridget F. Koontz, et al. “Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center..” The Journal of Urology 187, no. 1 (January 2012): 103–8. https://doi.org/10.1016/j.juro.2011.09.040.
    Full Text
  - Araujo, JC, Mathew, P, Armstrong, AJ, Braud, EL, Posadas, E, Lonberg, M, Gallick, GE, Trudel, GC, Paliwal, P, Agrawal, S, and Logothetis, CJ. "Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study." Cancer 118, no. 1 (January 2012): 63-71. Full Text
  - Bitting, RL, and Armstrong, AJ. "Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer." American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting (January 2012): 292-297. Full Text
  - Armstrong, Andrew J. “Epithelial-mesenchymal transition in cancer progression..” Clinical Advances in Hematology & Oncology : H&O 9, no. 12 (December 2011): 941–43.
  - Armstrong, Andrew J., Anna C. Ferrari, and David I. Quinn. “The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer..” Clinical Advances in Hematology & Oncology : H&O 9, no. 12 Suppl 28 (December 2011): 1–14.
  - Armstrong, AJ. "Clinical update: Epithelial-mesenchymal transition in cancer progression." Clinical Advances in Hematology and Oncology 9, no. 12 (December 1, 2011): 941-943.
  - Pili, Roberto, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasileios J. Assikis, Anders Björk, Orjan Nordle, Goran Forsberg, Michael A. Carducci, and Andrew J. Armstrong. “Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 30 (October 2011): 4022–28. https://doi.org/10.1200/jco.2011.35.6295.
    Full Text
  - Antonarakis, E. S., and A. J. Armstrong. “Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer..” Prostate Cancer and Prostatic Diseases 14, no. 3 (September 2011): 206–18. https://doi.org/10.1038/pcan.2011.24.
    Full Text
  - Sonpavde, Guru, Gregory R. Pond, William R. Berry, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, and Andrew J. Armstrong. “The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy..” Cancer 117, no. 17 (September 2011): 3963–71. https://doi.org/10.1002/cncr.25982.
    Full Text
  - Antonarakis, ES, and Armstrong, AJ. "Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer." Prostate Cancer and Prostatic Diseases 14, no. 3 (September 2011): 192-205. (Review) Full Text
  - Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, Gabor Kemeny, Rhonda L. Bitting, James D. Turnbull, Christina I. Herold, Paul K. Marcom, Daniel J. George, and Mariano A. Garcia-Blanco. “Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers..” Molecular Cancer Research : Mcr 9, no. 8 (August 2011): 997–1007. https://doi.org/10.1158/1541-7786.MCR-10-0490.
    Full Text
  - Bitting, Rhonda L., John Madden, and Andrew J. Armstrong. “Therapy for non-clear cell histologies in renal cancer..” Current Clinical Pharmacology 6, no. 3 (August 2011): 169–80.
  - Fleming, MT, Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Matveev, VB, Burke, JM, Caton, JR, and Sonpavde, G. "Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP)." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): e15019-e15019. Full Text
  - Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Berry, WR, De Wit, R, Eisenberger, MA, Tannock, I, and Sonpavde, G. "Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 4582-4582. Full Text
  - Fleming, M. T., G. R. Pond, A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, V. B. Matveev, J. M. Burke, J. R. Caton, and G. Sonpavde. “Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
  - Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, and G. Sonpavde. “Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
  - Armstrong, A. J., M. Haggman, W. M. Stadler, J. R. Gingrich, V. J. Assikis, O. Nordle, G. Forsberg, M. A. Carducci, and R. Pili. “Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups..” Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 126–126. https://doi.org/10.1200/jco.2011.29.7_suppl.126.
    Full Text
  - Armstrong, A. J., M. Haggman, W. M. Stadler, J. R. Gingrich, V. J. Assikis, O. Nordle, G. Forsberg, M. A. Carducci, and R. Pili. “Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011).
  - Armstrong, Andrew J., Stephen J. Freedland, and Mariano Garcia-Blanco. “Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy..” Asian Journal of Andrology 13, no. 2 (March 2011): 179–80. https://doi.org/10.1038/aja.2010.169.
    Full Text
  - Pond, G. R., A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, J. M. Burke, J. R. Caton, M. T. Fleming, and G. Sonpavde. “Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011).
  - Sonpavde, G., G. R. Pond, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, and A. J. Armstrong. “Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011).
  - Pond, GR, Armstrong, AJ, Wood, BA, Brookes, M, Leopold, LH, Burke, JM, Caton, JR, Fleming, MT, and Sonpavde, G. "Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 185-185. Full Text
  - Sonpavde, G, Pond, GR, Berry, WR, De Wit, R, Eisenberger, MA, Tannock, I, and Armstrong, AJ. "Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy." Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 118-118. Full Text
  - Armstrong, AJ. "Radiotherapy aids survival in clinically staged, node+ prostate Ca: Commentary." Oncology Report , no. JANUARY (January 1, 2011): 25-null.
  - Armstrong, AJ. "RT mode has an impact on pelvic fracture risk in older patients: Commentary." Oncology Report , no. JANUARY (January 1, 2011): 25-null.
  - Bitting, RL, Armstrong, AJ, and George, DJ. "Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?." Clinical Medicine Insights. Oncology 5 (January 2011): 325-332. Full Text
  - Chekeni, Faraaz B., Michael R. Elliott, Joanna K. Sandilos, Scott F. Walk, Jason M. Kinchen, Eduardo R. Lazarowski, Allison J. Armstrong, et al. “Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis..” Nature 467, no. 7317 (October 2010): 863–67. https://doi.org/10.1038/nature09413.
    Full Text
  - Armstrong, AJ. "Metastatic CRPC survival doesn't improve with added bevacizumab: Comment." Oncology Report , no. JULY-AUGUST (July 1, 2010): 23-null.
  - Armstrong, AJ. "Denosumab prevents or stalls skeletal events in prostate cancer: Comment." Oncology Report , no. JULY-AUGUST (July 1, 2010): 23-null.
  - Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, et al. “A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 16, no. 11 (June 2010): 3057–66. https://doi.org/10.1158/1078-0432.CCR-10-0124.
    Full Text
  - Armstrong, AJ, and George, DJ. "Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer." Prostate Cancer and Prostatic Diseases 13, no. 2 (June 2010): 108-116. (Review) Full Text
  - Armstrong, A. J. “IMPACT update: Survival benefit of sipuleucel-T is durable: Commentary.” Oncology Report, no. MARCH-APRIL (May 20, 2010).
  - Armstrong, A. J., D. J. George, and S. Halabi. “Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Armstrong, A. J., G. Kemeny, J. D. Turnbull, C. Chao, C. Winters, Y. A. Fesko, D. A. Bradley, S. Halabi, D. J. George, and M. Garcia-Blanco. “Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study..” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS249–TPS249. https://doi.org/10.1200/jco.2010.28.15_suppl.tps249.
    Full Text
  - Pili, R., M. Haggman, W. M. Stadler, J. R. Gingrich, V. J. Assikis, A. Bjork, G. Forsberg, M. A. Carducci, and A. J. Armstrong. “A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Sankhala, K. K., E. G. Chiorean, A. J. Armstrong, M. J. Borad, A. M. Traynor, S. M. Gadgeel, V. K. Langmuir, C. Eng, S. Kroll, and H. Burris. “Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC)..” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): e13527–e13527. https://doi.org/10.1200/jco.2010.28.15_suppl.e13527.
    Full Text
  - Turnbull, J. D., A. J. Armstrong, K. Morris, SE Yenser Wood, S. Voyles, Y. A. Fesko, and D. J. George. “A single arm phase Ib study of RAD001 and sunitinib in patients with advanced renal cell carcinoma (RCC)..” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Armstrong, AJ. "Cabazitaxel prolongs survival in late metastatic CRPC: Commentary." Oncology Report , no. MARCH-APRIL (May 20, 2010): 22-null.
  - Pond, GR, Sonpavde, G, Berry, WR, De Wit, R, Armstrong, AJ, Eisenberger, MA, and Tannock, I. "Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 4637-4637. Full Text
  - Armstrong, AJ, Tannock, IF, de Wit, R, George, DJ, Eisenberger, M, and Halabi, S. "The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival." European Journal of Cancer (Oxford, England : 1990) 46, no. 3 (February 2010): 517-525. Full Text
  - Armstrong, AJ, Garrett-Mayer, E, de Wit, R, Tannock, I, and Eisenberger, M. "Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 16, no. 1 (January 2010): 203-211. Full Text
  - Armstrong, AJ, Gebre, AK, Parks, JS, and Hedrick, CC. "ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation." Journal of Immunology (Baltimore, Md. : 1950) 184, no. 1 (January 2010): 173-183. Full Text
  - Armstrong, AJ. "TroVax vaccine delivers mixed results in renal cell carcinoma: Commentary." Oncology Report , no. WINT (December 1, 2009): 26-null.
  - Armstrong, AJ. "Bevacizumab increases toxicity, VTE in bladder cancer: Commentary." Oncology Report , no. FALL (September 1, 2009): 24-null.
  - Armstrong, AJ. "Second vaccine shows improved survival in prostate cancer: Commentary." Oncology Report , no. FALL (September 1, 2009): 25-null.
  - Armstrong, Andrew J., and Phillip G. Febbo. “Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature..” The Oncologist 14, no. 8 (August 14, 2009): 816–27. https://doi.org/10.1634/theoncologist.2009-0043.
    Full Text
  - Araujo, J., A. J. Armstrong, E. L. Braud, E. Posadas, M. Lonberg, G. E. Gallick, G. C. Trudel, P. Paliwal, S. Agrawal, and C. J. Logothetis. “Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009).
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. DeWit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009).
  - Armstrong, AJ, Halabi, S, de Wit, R, Tannock, IF, and Eisenberger, M. "The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer." Prostate Cancer and Prostatic Diseases 12, no. 1 (January 2009): 88-93. Full Text
  - Armstrong, AJ, Creel, P, Turnbull, J, Moore, C, Jaffe, TA, Haley, S, Petros, W, Yenser, S, Gockerman, JP, Sleep, D, Hurwitz, H, and George, DJ. "A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 14, no. 19 (October 2008): 6270-6276. Full Text
  - Figlin, Robert A., Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson, Harold J. Burstein, David S. Ettinger, et al. “NCCN Task Force Report: mTOR inhibition in solid tumors..” Journal of the National Comprehensive Cancer Network : Jnccn 6 Suppl 5 (September 2008): S1-20.
  - Armstrong, AJ. "Abiraterone acetate active in castration-resistant trials: Commentary." Oncology Report , no. FALL (September 1, 2008): 39-null.
  - Armstrong, AJ. "Thalidomide prolongs PFS following androgen failure: Commentary." Oncology Report , no. FALL (September 1, 2008): 40-null.
  - Armstrong, Andrew J., and Daniel J. George. “New drug development in metastatic prostate cancer..” Urologic Oncology 26, no. 4 (July 2008): 430–37. https://doi.org/10.1016/j.urolonc.2007.11.006.
    Full Text
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. Ronald, and M. A. Eisenberger. “The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 5074–5074. https://doi.org/10.1200/jco.2008.26.15_suppl.5074.
    Full Text
  - Whang, Y. E., C. N. Moore, A. J. Armstrong, W. K. Rathmell, P. A. Godley, J. M. Crane, G. I. Grigson, K. Morris, C. P. Watkins, and D. J. George. “A phase II trial of lapatinib in hormone refractory prostate cancer.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).
    Link to Item
  - Ramiah, Veshana, Daniel J. George, and Andrew J. Armstrong. “Clinical endpoints for drug development in prostate cancer..” Current Opinion in Urology 18, no. 3 (May 2008): 303–8. https://doi.org/10.1097/mou.0b013e3282fb7807.
    Full Text
  - Armstrong, AJ, Garrett-Mayer, EL, and Eisenberger, M. "Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens." Journal of the National Cancer Institute 100, no. 9 (May 2008): 681-682. (Letter) Full Text
  - Chen, FL, Armstrong, AJ, and George, DJ. "Cell signaling modifiers in prostate cancer." Cancer Journal (Sudbury, Mass.) 14, no. 1 (January 2008): 40-45. (Review) Full Text
  - Armstrong, AJ, Garrett-Mayer, E, Eisenberger, M, Tannock, I, and De Wit, R. "In reply [12]." Journal of Clinical Oncology 25, no. 35 (December 10, 2007): 5674-null. (Letter) Full Text
  - Armstrong, AJ, Garrett-Mayer, ES, Yang, Y-CO, de Wit, R, Tannock, IF, and Eisenberger, M. "A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 13, no. 21 (November 2007): 6396-6403. Full Text
  - Armstrong, Andrew J., and Daniel J. George. “Satraplatin in the treatment of hormone-refractory metastatic prostate cancer..” Therapeutics and Clinical Risk Management 3, no. 5 (October 2007): 877–83.
  - Armstrong, AJ, Garrett-Mayer, E, Ou Yang, Y-C, Carducci, MA, Tannock, I, de Wit, R, and Eisenberger, M. "Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 25 (September 2007): 3965-3970. Full Text
  - Srinivasan, Ramaprasad, Andrew J. Armstrong, William Dahut, and Daniel J. George. “Anti-angiogenic therapy in renal cell cancer..” Bju International 99, no. 5 Pt B (May 2007): 1296–1300. https://doi.org/10.1111/j.1464-410x.2007.06834.x.
    Full Text
  - Armstrong, A. J., P. G. Febbo, D. J. George, and J. Moul. “Systemic strategies for prostate cancer..” Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology 59, no. 1 (March 2007): 11–25.
  - Mendiratta, Prateek, Andrew J. Armstrong, and Daniel J. George. “Current standard and investigational approaches to the management of hormone-refractory prostate cancer..” Reviews in Urology 9 Suppl 1 (January 2007): S9–19.
  - Armstrong, Andrew J., and Mario Eisenberger. “Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?.” Nature Clinical Practice. Urology 3, no. 5 (May 2006): 246–47. https://doi.org/10.1038/ncpuro0462.
    Full Text
  - Armstrong, Andrew J., and Michael A. Carducci. “New drugs in prostate cancer..” Current Opinion in Urology 16, no. 3 (May 2006): 138–45. https://doi.org/10.1097/01.mou.0000193390.69845.bb.
    Full Text
  - Armstrong, AJ, and Carducci, MA. "Advanced prostate cancer: the future." The Canadian Journal of Urology 12 Suppl 2 (June 2005): 42-47. (Review)
  - Armstrong, Andrew J., and Michael A. Carducci. “Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies..” Current Oncology Reports 7, no. 3 (May 2005): 220–27. https://doi.org/10.1007/s11912-005-0077-y.
    Full Text
  - Armstrong, AJ, and Carducci, MA. "Novel therapeutic approaches to advanced prostate cancer." Clinical Advances in Hematology & Oncology : H&O 3, no. 4 (April 2005): 271-282. (Review)
  - Eck, SL, and Armstrong, A. "EpCAM is an important suppressor of anti-tumor immunity [2]." Cancer Biology and Therapy 4, no. 4 (April 1, 2005). (Letter)
  - Armstrong, Amy J., Brian T. McMahon, Steven L. West, and Allen Lewis. “Workplace discrimination and cumulative trauma disorders: the national EEOC ADA research project..” Work (Reading, Mass.) 25, no. 1 (January 2005): 49–56.
  - Armstrong, Andrew, and Stephen L. Eck. “EpCAM: A new therapeutic target for an old cancer antigen..” Cancer Biology & Therapy 2, no. 4 (July 2003): 320–26. https://doi.org/10.4161/cbt.2.4.451.
    Full Text
  - Nightingale, R. W., D. L. Camacho, A. J. Armstrong, J. J. Robinette, and B. S. Myers. “Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine..” Journal of Biomechanics 33, no. 2 (February 2000): 191–97. https://doi.org/10.1016/s0021-9290(99)00156-6.
    Full Text
  - Nightingale, RW, Armstrong, AJ, Camacho, DL, and Myers, BS. "Cervical spine buckling: The effects of vertebral mass and loading rate." American Society of Mechanical Engineers, Bioengineering Division (Publication) Bed 36 (1997): 231-232.
  - Fukasawa, K., R. Zhou, W. T. Matten, A. J. Armstrong, I. Daar, M. Oskarsson, B. K. Sathyanarayana, L. Maclvor, T. G. Wood, and G. F. Vande Woude. “Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding..” Oncogene 11, no. 8 (October 1995): 1447–57.
  - Bevan, T. D., A. J. Manninen, J. B. Cook, A. J. Armstrong, J. R. Hook, and H. E. Hall. “Vortex Mutual Friction in Rotating Superfluid 3He-B..” Physical Review Letters 74, no. 5 (January 1995): 750–53. https://doi.org/10.1103/physrevlett.74.750.
    Full Text
  - Mullins, T. R., V. V. Dmitriev, A. J. Armstrong, A. J. Manninen, J. R. Hook, and H. E. Hall. “Identification of the order parameter of 3He-A using low-field NMR measurements..” Physical Review Letters 72, no. 26 (June 1994): 4117–20. https://doi.org/10.1103/physrevlett.72.4117.
    Full Text
  - Tang, Y., A. J. Armstrong, R. C. Mockler, and W. J. O’Sullivan. “Free-expansion melting of a colloidal monolayer..” Physical Review Letters 62, no. 20 (May 1989): 2401–4. https://doi.org/10.1103/physrevlett.62.2401.
    Full Text
  - Bender, D. A., A. J. Armstrong, C. R. Monkhouse, and J. P. Richardson. “Changes in pancreatic tryptophan in the rat in response to fasting. The effect of B-cytotoxic agents and variation through the oestrous cycle..” Pflugers Archiv : European Journal of Physiology 356, no. 3 (January 1975): 245–51. https://doi.org/10.1007/bf00583836.
    Full Text
  - Freedland, SJ, Howard, L, Allen, J, Smith, J, Stout, J, Aronson, W, Inman, BA, Armstrong, AJ, George, D, Westman, E, and Lin, P-H. "A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial." Prostate Cancer and Prostatic Diseases (January 21, 2019). Full Text
- Book Sections
  - Li, J, and Armstrong, AJ. "Prognostic and predictive biomarkers for castration resistant prostate cancer." In Biomarkers in Disease: Methods, Discoveries and Applications: Biomarkers in Cancer, 447-480. January 1, 2015. Full Text
  - Armstrong, AJ, and Carducci, MA. "Chemotherapy for advanced prostate cancer." In Treatment Methods for Early and Advanced Prostate Cancer, 327-339. January 1, 2008.
  - Armstrong, AJ, and Carducci, MA. "Chemotherapy for advanced prostate cancer." In Prostate Cancer: Principles and Practice, 989-1003. January 1, 2005.
- Other Articles
  - Somarelli, JA, Schaeffer, D, Marengo, MS, Bepler, T, Rouse, D, Buckley, AF, Epstein, JI, Armstrong, AJ, and Garcia-Blanco, MA. "Abstract SS02-02: A long walk from FGFR2 alternative splicing to cancer progression." Cell, Molecular, and Tumor Biology (November 2014). Full Text
  - Armstrong, Andrew J., Judd W. Moul, and Daniel J. George. “What to order from the prostate cancer treatment menu?.” Oncology (Williston Park, N.Y.), January 2012.
  - Armstrong, Andrew J., Judd W. Moul, and Daniel J. George. “What to Order From the Prostate Cancer Treatment Menu? THE CRAWFORD/FLAIG ARTICLE REVIEWED.” Oncology New York. UBM MEDICA, January 1, 2012.
    Link to Item
- Conference Papers
  - Harrison, MR, Davis, PG, Khouri, MG, Gupta, RT, Armstrong, AJ, McNamara, MA, Zhang, T, Anand, M, Onyenwoke, K, Hood, H, Edwardson, S, Craig, D, Wu, Y, Healy, P, Coyne, B, Jones, L, and George, DJ. "EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naive prostate cancer (HSPC)." 43rd ESMO Congress (ESMO). Munich, GERMANY. October 19, 2018 - October 23, 2018.: OXFORD UNIV PRESS, October 1, 2018. Link to Item
  - George, DJ, Heath, EI, Sartor, AO, Sonpavde, G, Berry, WR, Healy, P, Winters, C, Riggan, C, Anand, M, Kephart, J, Milowsky, MI, Fleming, MT, Balaji, KC, Zhang, T, Bitting, RL, Harrison, MR, McNamara, MA, Freedman, JA, Halabi, S, Armstrong, AJ, and Bruner, D. "Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP)." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 1, 2018 - June 5, 2018.: AMER SOC CLINICAL ONCOLOGY, June 20, 2018. Link to Item
  - Armstrong, AJ, Gupta, S, Healy, P, Kemeny, G, Leith, LB, Zalutsky, M, Spritzer, C, Davies, C, Ware, K, Somarelli, J, Wood, K, Glover, W, Hsu, SD, Gerber, D, Rothwell, C, Mundy, K, Anand, M, Gregory, S, Halabi, S, and George, DJ. "Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - Concepcion, R, Armstrong, AJ, Karsh, LI, Holmstrom, S, Ivanescu, C, Dunshee, C, Agarwal, N, O'Kelly, M, Naidoo, S, Olsson, CA, Phung, D, Ratitch, B, Wang, F, Kral, P, and Penson, DF. "Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - Freedland, SJ, Allen, J, Armstrong, AJ, Moul, JW, Sandler, HM, Levin, D, Howard, LE, and Lin, P-H. "Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2 (CAPS2)." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - Koontz, BF, Hoffman, KE, Healy, P, George, DJ, Harrison, MR, Zhang, T, Lee, WR, Berry, WR, Pugh, TJ, Corn, PG, Bratt, L, Shobe, K, Thornburg, B, Allen, DM, Brummer, K, Tojong, B, Hobbs, B, Halabi, S, and Armstrong, AJ. "Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - McNamara, MA, Ritz, M, Chin, B, Oldan, J, Anand, A, Oyekunle, T, Anand, M, Armstrong, AJ, and George, DJ. "Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC)." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - Sumanasuriya, S, Omlin, AG, Armstrong, AJ, Attard, G, Chi, KN, Bevan, CL, Waugh, DJ, Ijzerman, MJ, De Laere, B, Lolkema, MP, Lorente, D, Luo, J, Mehra, N, Olmos, D, Scher, HI, Soule, HR, Stoecklein, NH, Terstappen, LWMM, and De Bono, JS. "Consensus statement on circulating biomarkers for advanced prostate cancer." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - Zhang, T, Austin, RG, Park, SE, Runyambo, D, Boominathan, R, Rao, C, Bronson, E, Anand, M, Healy, P, George, DJ, McNamara, MA, and Armstrong, AJ. "Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC)." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - Zhu, J, Tucker, MD, Healy, P, Humeniuk, MS, Jarvis, C, George, DJ, and Armstrong, AJ. "Clinical utility of Foundation One tissue molecular profiling in men with metastatic prostate cancer." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - Armstrong, A. J., P. Lin, C. S. Higano, P. Iversen, C. N. Sternberg, B. Tombal, D. Phung, T. Parli, A. Krivoshik, and T. M. Beer. “Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naiive men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
    Link to Item
  - Armstrong, AJ, Halabi, S, Healy, P, Alumkal, JJ, Winters, C, Kephart, J, Bitting, RL, Hobbs, C, Soleau, CF, Beer, TM, Slottke, R, Mundy, K, Yu, EY, and George, DJ. "Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer." August 2017. Full Text
  - Armstrong, A, Bui, C, Fitch, K, Sawhney, TG, Brown, B, Flanders, S, Balk, M, Deangelis, J, and Chambers, J. "Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations." June 2017. Full Text
  - Armstrong, AJ, Humeniuk, MS, Healy, P, Szmulewitz, R, Winters, C, Kephart, J, Harrison, MR, Martinez, E, Mundy, K, Halabi, S, and George, D. "Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial." United States. March 2017. Full Text Link to Item
  - Beer, TM, Armstrong, AJ, Rathkopf, D, Loriot, Y, Sternberg, CN, Higano, CS, Iversen, P, Evans, CP, Kim, C-S, Kimura, G, Miller, K, Saad, F, Bjartell, AS, Borre, M, Mulders, P, Tammela, TL, Parli, T, Sari, S, van Os, S, Theeuwes, A, and Tombal, B. "Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study." February 2017. Full Text
  - Sternberg, C, Armstrong, A, Pili, R, Ng, S, Huddart, R, Agarwal, N, Khvorostenko, D, Lyulko, O, Brize, A, Vogelzang, N, Delva, R, Harza, M, Thanos, A, James, N, Werbrouck, P, Bögemann, M, Hutson, T, Milecki, P, Chowdhury, S, Gallardo, E, Schwartsmann, G, Pouget, J-C, Baton, F, Nederman, T, Tuvesson, H, and Carducci, M. "Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer." August 2016. Full Text
  - Armstrong, AJ, Halabi, S, Healy, P, Lee, WR, Koontz, BF, Moul, JW, Mundy, K, Creel, P, Wood, S, Davis, K, Carducci, MA, Stein, M, Hobbs, C, Reimer, B, Nguyen, M, Anand, M, Bratt, L, Kim, S, Tran, PT, George, DJ, and Department of Defense Prostate Cancer Clinical Trials Consortium, . "A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy." March 2016. Full Text
  - Armstrong, Andrew J., Fred Saad, Neal D. Shore, Karim Fizazi, De Phung, Carl Frank Dmuchowski, Mohammad Hirmand, David Forer, Howard I. Scher, and Johann S. De Bono. “Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM..” In Journal of Clinical Oncology, 34:266–266. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.266.
    Full Text
  - George, Daniel J., Susan Halabi, Patrick Healy, Sarah Gemberling, Carolyn Winters, Kelly Mundy, Michael Roger Harrison, Russell Zelig Szmulewitz, and Andrew J. Armstrong. “Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC)..” In Journal of Clinical Oncology, 34:275–275. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.275.
    Full Text
  - Higano, Celestia S., Andrew J. Armstrong, Matthew R. Cooperberg, Raoul S. Concepcion, Ronald F. Tutrone, Carl A. Olsson, Christopher Michael Pieczonka, et al. “Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use..” In Journal of Clinical Oncology, 34:193–193. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.193.
    Full Text
  - Morris, Michael J., Tomasz M. Beer, Yohann Loriot, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann S. De Bono, et al. “Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL..” In Journal of Clinical Oncology, 34:182–182. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.182.
    Full Text
  - Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, Kenneth Wu, Fong Wang, Andrew P. Krivoshik, De Phung, and Celestia S. Higano. “Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC)..” In Journal of Clinical Oncology, 34:169–169. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.169.
    Full Text
  - Sartor, A Oliver, Matthew R. Cooperberg, Andrew J. Armstrong, Nicholas J. Vogelzang, Jeffrey L. Vacirca, Mark C. Scholz, Shaker R. Dakhil, et al. “Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry..” In Journal of Clinical Oncology, 34:194–194. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.194.
    Full Text
  - Sternberg, Cora N., Andrew J. Armstrong, Roberto Pili, Tore Nederman, and Michael Anthony Carducci. “A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints..” In Journal of Clinical Oncology, 34:239–239. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.239.
    Full Text
  - Armstrong, AJ, Higano, CS, Sartor, AO, Vogelzang, NJ, Berry, WR, Penson, DF, Kassabian, V, Nordquist, LT, Chang, NN, LIll, JS, and Cooperberg, MR. "Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry." : American Society of Clinical Oncology (ASCO), January 10, 2016. Full Text
  - Ware, KE, Schaeffer, D, Zhang, T, Garcia-Blanco, MA, and Armstrong, AJ. "Abstract 1847: AR-V7 regulation during epithelial plasticity." : American Association for Cancer Research (AACR), August 1, 2015. Full Text
  - Armstrong, Andrew J., Samuel Broderick, Tim Eisen, Walter Michael Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, et al. “Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, John H. Strickler, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies..” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Higano, CS, Sartor, AO, Vogelzang, NJ, Dakhil, SR, Concepcion, RS, Pieczonka, CM, Vacirca, JL, Tutrone, RF, Olsson, CA, Penson, DF, Biggs, C, LIll, JS, Gray, TE, McCoy, C, Cooperberg, MR, and Armstrong, AJ. "Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry." : American Society of Clinical Oncology (ASCO), May 20, 2015. Full Text
  - Li, J, Beaver, J, Bitting, RL, Gregory, S, and Armstrong, AJ. "Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy." : American Society of Clinical Oncology (ASCO), May 20, 2015. Full Text
  - Morris, MJ, Hilden, P, Gleave, ME, Armstrong, AJ, Carducci, MA, Saad, F, Dayan, ES, Filipenko, J, Acosta, I, Heller, G, and Scher, HI. "Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy." : American Society of Clinical Oncology (ASCO), May 20, 2015. Full Text
  - Scher, HI, Morris, MJ, Stadler, WM, Higano, CS, Halabi, S, Smith, MR, Basch, EM, Fizazi, K, Ryan, CJ, Antonarakis, ES, Corn, PG, Liu, G, De Bono, JS, Schwartz, LH, Beer, TM, Kelly, WK, Hussain, M, Sartor, AO, Kantoff, PW, and Armstrong, AJ. "The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC)." : American Society of Clinical Oncology (ASCO), May 20, 2015. Full Text
  - Tutrone, Ronald F., Chiledum Ahaghotu, Andrew J. Armstrong, Celestia S. Higano, Matthew R. Cooperberg, Laurence H. Belkoff, Carl A. Olsson, et al. “Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience..” In Journal of Clinical Oncology, 33:272–272. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.7_suppl.272.
    Full Text
  - Graff, JN, Baciarello, G, Armstrong, AJ, Higano, CS, Iversen, P, Forer, D, Mansbach, HH, Phung, D, Tombal, BF, Beer, TM, and Sternberg, CN. "Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial." : American Society of Clinical Oncology (ASCO), March 2015. Full Text
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, Herbert Hurwitz, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies..” In Journal of Clinical Oncology, 33:84–84. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.84.
    Full Text
  - Bhavsar, N. A., M. R. Harrison, L. J. Howie, A. J. Armstrong, K. Davis, Q. Chen, M. R. Pupa, A. Abernethy, D. J. George, and B. R. Hirsch. “1072PEXPERIENCE OF PATIENTS TREATED WITH SIPULEUCEL-T IN AN ACADEMIC SETTING..” In Annals of Oncology : Official Journal of the European Society for Medical Oncology, 25:iv369–70, 2014.
  - Furay, A, Nordquist, LT, Dakhil, SR, Green, NB, Heath, EI, Tutrone, RF, Vogelzang, NJ, Armstrong, AJ, Cooperberg, MR, Tyler, RC, Whitmore, JB, and Higano, CS. "Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients." : Elsevier BV, September 2014. Full Text
  - Armstrong, AJ, Tombal, B, Sternberg, CN, Higano, CS, Rathkopf, DE, Loriot, Y, Saad, F, Joshua, AM, De Bono, JS, Venner, PM, Carles, J, Mainwaring, PN, Evans, CP, Noonberg, SB, Mansbach, HH, Bhattacharya, S, Perabo, F, Phung, D, and Beer, TM. "Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC)." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Halabi, S, Kelly, WK, Zhou, H, Armstrong, AJ, Quinn, D, Fizazi, K, Solomon, NC, Tannock, I, Petrylak, DP, Morris, MJ, and Small, EJ. "The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Li, J, Beaver, J, Bitting, RL, Gregory, S, and Armstrong, AJ. "Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Morris, MJ, Gleave, ME, Armstrong, AJ, Carducci, MA, Saad, F, Lacuna, KP, and Scher, HI. "A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Morris, MJ, Loriot, Y, Beer, TM, Higano, CS, Armstrong, AJ, Sternberg, CN, De Bono, JS, Tombal, BF, Noonberg, SB, Mansbach, HH, Bhattacharya, S, Perabo, F, Phung, D, and Rathkopf, DE. "Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Zhang, T, Dhawan, MS, Healy, P, George, DJ, Oldan, J, Chin, B, and Armstrong, AJ. "Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC)." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Armstrong, AJ, Bitting, RL, Kemeny, G, and George, DJ. "Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment." : American Society of Clinical Oncology (ASCO), February 2014. Full Text
  - Armstrong, AJ, Li, J, Beaver, J, Bitting, RL, and Gregory, S. "Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy." : American Society of Clinical Oncology (ASCO), February 2014. Full Text
  - Beer, TM, Armstrong, AJ, Sternberg, CN, Higano, CS, Iversen, P, Loriot, Y, Rathkopf, DE, Bhattacharya, S, Carles, J, De Bono, JS, Evans, CP, Joshua, AM, Kim, C-S, Kimura, G, Mainwaring, PN, Mansbach, HH, Miller, K, Noonberg, SB, Venner, PM, and Tombal, B. "Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study." : American Society of Clinical Oncology (ASCO), February 2014. Full Text
  - Finkelstein, SE, Nordquist, LT, Dakhil, SR, Green, NB, Heath, EI, Tutrone, R, Vogelzang, NJ, Armstrong, AJ, Cooperberg, MR, Tyler, RC, Sims, RB, Whitmore, JB, and Higano, CS. "Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts)." : American Society of Clinical Oncology (ASCO), February 2014. Full Text
  - Nabhan, C, Sartor, AO, Cooperberg, MR, Armstrong, AJ, Vacirca, JL, Concepcion, RS, Berry, WR, Dhawan, M, Tutrone, R, Sandler, A, McCoy, C, Whitmore, JB, Tyler, RC, and Higano, CS. "Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: Data from PROCEED." : American Society of Clinical Oncology (ASCO), February 2014. Full Text
  - Vogelzang, NJ, Vacirca, JL, Kantoff, PW, Scholz, MC, Dakhil, SR, Nordquist, LT, Higano, CS, Sartor, AO, Cooperberg, MR, Sandler, A, McCoy, C, Whitmore, JB, Tyler, RC, and Armstrong, AJ. "Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts)." : American Society of Clinical Oncology (ASCO), February 2014. Full Text
  - Armstrong, Andrew J., Reza Kaboteh, Michael Anthony Carducci, Jan-Erik Damber, Walter Michael Stadler, Hansen Mats, Lars Edenbrandt, et al. “Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Armstrong, Andrew J., Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R. Jones, Ultra N. Vaishampayan, Jorge A. Garcia, et al. “ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Bitting, Rhonda Lynn, Patrick Healy, Susan Halabi, Daniel J. George, Jung Hyun Ko, and Andrew J. Armstrong. “Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC)..” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, et al. “A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Higano, Celestia S., Andrew J. Armstrong, Matthew R. Cooperberg, Philip W. Kantoff, James Bailen, Raoul S. Concepcion, Vahan Kassabian, et al. “Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts)..” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, et al. “A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.24.
    Full Text Link to Item
  - Scher, Howard I., Karim Fizazi, Fred Saad, Kim N. Chi, Mary-Ellen Taplin, Cora N. Sternberg, Andrew J. Armstrong, Mohammad Hirmand, David Forer, and Johann Sebastian De Bono. “Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.6.
    Full Text Link to Item
  - Schweizer, Michael Thomas, Aditya Bardia, Amanda L. Blackford, Jianqing Lin, Andrew J. Armstrong, Serina King, Michelle A. Rudek, Srinivasan Thomas Yegnasubramanian, and Michael Anthony Carducci. “A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.219.
    Full Text Link to Item
  - Armstrong, AJ, Shen, T, Halabi, S, Kemeny, G, Bitting, RL, Kartcheske, P, Embree, E, Morris, K, Winters, C, Jaffe, T, Fleming, MT, and George, DJ. "A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer." : American Society of Clinical Oncology (ASCO), February 20, 2013. Full Text
  - Corman, J., N. Dawson, S. Hall, C. Nabhan, A. Ferrari, A. J. Armstrong, M. I. Murdock, F. Stewart, N. Sheikh, and D. P. Petrylak. “OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC).” In Annals of Oncology, 23:311–311. OXFORD UNIV PRESS, 2012.
    Link to Item
  - Scher, H. I., K. Fizazi, F. Saad, K. Chi, M. Taplin, C. N. Sternberg, A. J. Armstrong, M. Hirmand, B. Selby, and J. S. de Bono. “ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI).” In Annals of Oncology, 23:297–297. OXFORD UNIV PRESS, 2012.
    Link to Item
  - Sonpavde, G., G. R. Pond, A. J. Armstrong, M. D. Galsky, B. A. Wood, S. Wang, J. Paolini, M. Lechuga, M. R. Smith, and M. D. Michaelson. “ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER.” In Annals of Oncology, 23:297–98. OXFORD UNIV PRESS, 2012.
    Link to Item
  - Armstrong, Andrew J., Michael Haggman, Walter Michael Stadler, Jeffrey R. Gingrich, Vasily J. Assikis, Jonathan Polikoff, Samuel R. Denmeade, et al. “Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Bitting, Rhonda Lynn, Rengasamy Boominathan, Chandra Rao, Elizabeth Embree, Daniel J. George, Mark C. Connelly, Gabor Kemeny, Mariano Garcia-Blanco, and Andrew J. Armstrong. “Isolation of circulating tumor cells using a novel EMT-based capture method..” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - De Bono, Johann Sebastian, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N. Sternberg, Kurt Miller, Peter Mulders, et al. “Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Halabi, Susan, Andrew J. Armstrong, A Oliver Sartor, Johann Sebastian De Bono, Ellen B. Kaplan, and Eric Jay Small. “Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium..” In Journal of Clinical Oncology, 29:4664–4664. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.4664.
    Full Text
  - Araujo, J., P. Mathew, A. J. Armstrong, E. L. Braud, E. Posadas, M. Lonberg, G. Gallick, G. C. Trudel, P. Paliwal, and C. J. Logothetis. “7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086.” In European Journal of Cancer Supplements, 7:415–415. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71406-5.
    Full Text
  - Araujo, J., A. J. Armstrong, E. L. Braud, E. Posadas, M. Lonberg, G. E. Gallick, G. C. Trudel, P. Paliwal, S. Agrawal, and C. J. Logothetis. “Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. Dewit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Armstrong, AJ. "Commentary." September 1, 2008.
  - Armstrong, AJ, Eisenberger, MA, Garrett-Mayer, ES, Yang, YO, Carducci, MA, de Wit, R, and Tannock, I. "Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC)." : AMER SOC CLINICAL ONCOLOGY, June 20, 2007. Link to Item
  - Eisenberger, M, Garrett-Mayer, ES, Yang, YO, de Wit, R, Tannock, I, and Armstrong, AJ. "A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC)." : AMER SOC CLINICAL ONCOLOGY, June 20, 2007. Link to Item
  - Speca, JC, Mears, AL, Creel, PA, Yenser, SE, Bendell, JC, Morse, MA, Hurwitz, HI, Armstrong, AJ, and George, DJ. "Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients." : AMER SOC CLINICAL ONCOLOGY, June 20, 2007. Link to Item
Teaching & Mentoring
Recent Courses
- PHARM 493: Research Independent Study 2019
- PHARM 494: Research Independent Study 2019

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

In the News

Global Scholarship

Research

Teaching

Selected Grants

Selected Publications

Academic Articles

Book Sections

Other Articles

Conference Papers

Recent Courses